SIEMENS



Reduce Risk of Ineffective Treatment Delivery

EQ·PET: Achieving NEMA-referenced SUV Across Technologies

usa.siemens.com/mi



Pre- and post-RT PET/CT scans for lung cancer patient. A single lesion in the right lung is identified and the quantitative assessment is dependent on the reconstruction method used. This dependency is minimized with EQ·PET.

Data courtesy of François Baclesse Cancer Centre, Caen, France.

In cancer therapy follow-up, reading physicians frequently receive prior exams of their patients that have been acquired with different scanners. Scanner and reconstruction parameters can significantly affect standard uptake value (SUV) measurements, making it difficult to assess early response to therapy when comparing data acquired from different scanners. If quantification results are not normalized, conclusions about therapy progress or tumor size changes will differ and can lead to ineffective therapies.

In order to reduce quantitative variability across scanners, Siemens has developed EQ·PET to harmonize clinical reading results regardless of scanner or reconstruction protocols.

EQ·PET is a reference-based quantification technology within *syngo*®.via that provides an overarching solution across all vendors and platforms to equalize and calibrate systems to have a common baseline to compare SUVs.

Bridging Systems, Platforms, and Protocols in Oncology

With EQ·PET, radiologists can read from the original patient image, reconstructed with their preferred protocol, to maximize image quality and detectability. The EQ·PET technology does the work: SUV is harmonized by a parameter that aligns systems and reconstructions. This improves the comparability and consistency of SUVs across scanners to impact the efficiency and efficacy of patient care to help reduce costs as a result of ineffective therapies.

Ineffective therapies can exceed $92,000 annually per patient.[1] Accurate therapy monitoring supports physicians to deliver efficient and cost-effective care for their patients.

Overall EQ·PET enables clinicians to:

- Quantitatively assess treatment response in patients, even if imaged on different PET/CT systems.
- Participate in multi-center clinical trials, without modifying reconstruction protocols.
- Utilize SUV based thresholds that may aid in better informed patient therapy decisions—even if they were defined on an older PET/CT system.

Ineffective therapies
$92,000
annually per patient

To learn more about EQ·PET, part of *syngo*.via, visit **usa.siemens.com/mi** or call 1-888-826-9702 and ask to speak to your local sales representative.

[1] High Price of Cancer Drugs Is Harming Patients. Medscape Medical News Web site. medscape.com/viewarticle/803415. Accessed May 10, 2015.

Siemens Healthcare Headquarters
Siemens Healthcare GmbH
Henkestraße 127
91052 Erlangen
Germany
Phone: +49 9131 84-0
siemens.com/healthcare

Global Business Unit
Siemens Medical Solutions USA, Inc.
Molecular Imaging
2501 N. Barrington Road
Hoffman Estates, IL 60192-2061
USA
Phone: +1-888-826-9702
usa.siemens.com/healthcare

Local Contact Information
Siemens Medical Solutions USA, Inc.
40 Liberty Boulevard
Malvern, PA 19355-9998
USA
Phone: +1-888-826-9702
usa.siemens.com/healthcare

Order No. A911IM-MI-152091-P1-4A00 | Printed in USA 11-2015 |

siemens.com/healthcare